Payment overview · 2025
General Payments
$3,010.20
57 reported records · 21 companies
Healthcare provider profile · identity verified
David E Steiner, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · HOLLYWOOD, FL · NPI 1093896722
Verified facts
What the public records show
CMS Open Payments records show David E Steiner, M.D. received $3,010.20 in general payments during 2025 across 57 reported records.
AngioDynamics, Inc. accounted for 53.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Eliquis, Ozempic, Paxlovid, Verquvo.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 313 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Trelegy Ellipta by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERQUVO as an associated drug or biological on 38060 records involving 12268 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Verquvo by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 313 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $1,600.00 | 53.1% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $346.06 | 11.5% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $193.59 | 6.4% | 9 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $136.89 | 4.5% | 7 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $84.51 | 2.8% | 5 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $83.58 | 2.8% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $83.18 | 2.8% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $79.26 | 2.6% | 4 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$72.06 | 2.4% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $66.10 | 2.2% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $64.89 | 2.2% | 3 | 2025 |
| AtriCure, Inc. | Unresolved — no canonical attribution shown | $29.12 | 1.0% | 1 | 2025 |
| Medicure Pharma Inc. | Unresolved — no canonical attribution shown | $24.27 | 0.8% | 1 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $22.36 | 0.7% | 1 | 2025 |
| Bard Peripheral Vascular, Inc. | Unresolved — no canonical attribution shown | $21.76 | 0.7% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.70 | 0.7% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $18.27 | 0.6% | 1 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $17.09 | 0.6% | 1 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $16.94 | 0.6% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $16.63 | 0.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.94 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Long term medical supply or device loan | $1,600.00 | 1 |
| Food and Beverage | $1,410.20 | 56 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VenaCure 1470 Pro Normalized: venacure 1470 pro |
Device | AngioDynamics, Inc. | $1,600.00 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $209.32 | 5 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $136.89 | 7 | 2025 |
Source payment records
|
|||||
| WATCHMAN Normalized: watchman |
Device | Boston Scientific Corporation | $136.74 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $124.82 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $90.55 | 4 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $83.58 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $83.18 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $79.26 | 4 | 2025 |
Source payment records
|
|||||
| VENASEAL Normalized: venaseal |
Device | Medtronic, Inc. | $72.06 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $66.10 | 3 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $61.65 | 3 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $50.24 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $40.94 | 2 | 2025 |
Source payment records
|
|||||
| SYNERGY ABLATION SYSTEM Normalized: synergy ablation system |
Device | AtriCure, Inc. | $29.12 | 1 | 2025 |
Source payment records
|
|||||
| Zypitamag Normalized: zypitamag |
Drug | Medicure Pharma Inc. | $24.27 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $23.95 | 1 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $22.36 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $22.36 | 1 | 2025 |
Source payment records
|
|||||
| Venclose Maven Catheter Normalized: venclose maven catheter |
Device | Bard Peripheral Vascular, Inc. | $21.76 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $21.39 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $21.39 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $21.39 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $20.33 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $19.70 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $18.27 | 1 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $17.09 | 1 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $16.94 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $16.63 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $13.94 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 28 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 313 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 69 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 14 | exact normalized | Medicare Part D |
| VERQUVO verquvo |
2025 | Verquvo | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
313 | 72 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
28 | 26 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | VERQUVO open payments reported associated product |
CMS Open Payments — General Payments 38060 supporting records · 12268 recipient NPIs · example record 1237992208 |
Verquvo · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
69 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
313 | 72 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 780 | 225 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 753 | 224 |
| Amlodipine Besylate | Amlodipine Besylate | 543 | 153 |
| Losartan Potassium | Losartan Potassium | 391 | 112 |
| Levothyroxine Sodium | Levothyroxine Sodium | 364 | 97 |
| Metoprolol Succinate | Metoprolol Succinate | 331 | 98 |
| Eliquis | Apixaban | 313 | 72 |
| Alprazolam | Alprazolam | 301 | 72 |
| Hydrochlorothiazide | Hydrochlorothiazide | 226 | 71 |
| Metformin Hcl | Metformin Hcl | 216 | 69 |
| Ezetimibe | Ezetimibe | 213 | 64 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 205 | 53 |
| Zolpidem Tartrate | Zolpidem Tartrate | 174 | 35 |
| Furosemide | Furosemide | 172 | 56 |
| Metoprolol Tartrate | Metoprolol Tartrate | 167 | 55 |
| Escitalopram Oxalate | Escitalopram Oxalate | 161 | 40 |
| Lisinopril | Lisinopril | 159 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 156 | 47 |
| Allopurinol | Allopurinol | 147 | 39 |
| Omeprazole | Omeprazole | 145 | 44 |
| Carvedilol | Carvedilol | 134 | 40 |
| Potassium Chloride | Potassium Chloride | 132 | 43 |
| Clonidine Hcl | Clonidine Hcl | 126 | 47 |
| Clopidogrel | Clopidogrel Bisulfate | 124 | 41 |
| Simvastatin | Simvastatin | 117 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 98 | 33 |
| Gabapentin | Gabapentin | 80 | 26 |
| Methylprednisolone | Methylprednisolone | 80 | 65 |
| Azithromycin | Azithromycin | 79 | 66 |
| Sertraline Hcl | Sertraline Hcl | 78 | 19 |
| Spironolactone | Spironolactone | 78 | 22 |
| Montelukast Sodium | Montelukast Sodium | 77 | 24 |
| Nifedipine Er | Nifedipine | 76 | 22 |
| Jardiance | Empagliflozin | 72 | 16 |
| Terazosin Hcl | Terazosin Hcl | 72 | 24 |
| Ozempic | Semaglutide | 69 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 66 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 65 | 24 |
| Amiodarone Hcl | Amiodarone Hcl | 65 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 64 | 18 |
| Alendronate Sodium | Alendronate Sodium | 63 | 16 |
| Meloxicam | Meloxicam | 63 | 19 |
| Trazodone Hcl | Trazodone Hcl | 63 | 16 |
| Telmisartan | Telmisartan | 62 | 17 |
| Tramadol Hcl | Tramadol Hcl | 60 | 19 |
| Temazepam | Temazepam | 59 | 12 |
| Metformin Hcl Er | Metformin Hcl | 57 | 17 |
| Xarelto | Rivaroxaban | 56 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 53 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 51 | 12 |
| Atenolol | Atenolol | 50 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 50 | 13 |
| Chlorthalidone | Chlorthalidone | 49 | 14 |
| Prednisone | Prednisone | 49 | 21 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 48 | 37 |
| Famotidine | Famotidine | 47 | 17 |
| Glipizide Er | Glipizide | 45 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 44 | suppressed |
| Repatha Sureclick | Evolocumab | 43 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 42 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 41 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 41 | suppressed |
| Valsartan | Valsartan | 41 | 12 |
| Vascepa | Icosapent Ethyl | 40 | 16 |
| Ibuprofen | Ibuprofen | 39 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 39 | 22 |
| Nebivolol Hcl | Nebivolol Hcl | 37 | suppressed |
| Clonazepam | Clonazepam | 36 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 36 | 13 |
| Lorazepam | Lorazepam | 36 | 13 |
| Mirtazapine | Mirtazapine | 36 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 35 | suppressed |
| Synthroid | Levothyroxine Sodium | 34 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 34 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 33 | 28 |
| Multaq | Dronedarone Hcl | 33 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 33 | suppressed |
| Brilinta | Ticagrelor | 31 | suppressed |
| Bumetanide | Bumetanide | 31 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | suppressed |
| Entresto | Sacubitril/Valsartan | 30 | suppressed |
| Finasteride | Finasteride | 30 | suppressed |
| Glimepiride | Glimepiride | 30 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 29 | 11 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 28 | 26 |
| Glipizide | Glipizide | 28 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 28 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 27 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 27 | suppressed |
| Irbesartan | Irbesartan | 27 | suppressed |
| Torsemide | Torsemide | 26 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 26 | suppressed |
| Diazepam | Diazepam | 25 | 11 |
| Nitroglycerin | Nitroglycerin | 25 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Praluent Pen | Alirocumab | 24 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 24 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Klor-Con 10 | Potassium Chloride | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Sotalol | Sotalol Hcl | 20 | suppressed |
| Amoxicillin | Amoxicillin | 19 | suppressed |
| Cefdinir | Cefdinir | 19 | 15 |
| Mounjaro | Tirzepatide | 19 | suppressed |
| Digoxin | Digoxin | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Gemtesa | Vibegron | 17 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 16 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Cilostazol | Cilostazol | 14 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 14 | suppressed |
| Famciclovir | Famciclovir | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Pindolol | Pindolol | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Verquvo | Vericiguat | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Nexletol | Bempedoic Acid | 12 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 11 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,010.20 · 57 records | AngioDynamics, Inc. | ABRYSVO, AREXVY, Barostim Neo System, CAMZYOS, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FFRct, Flexitouch Plus, Korlym, LEQVIO, NURTEC ODT, Nimbl, ONPATTRO, Ozempic, PAXLOVID, PREVNAR 20, Prolastin-C Liquid, REPATHA, SYNERGY ABLATION SYSTEM, The Cologuard Plus Collection Kit, VENASEAL, VERQUVO, VYNDAQEL, VenaCure 1470 Pro, Venclose Maven Catheter, WATCHMAN, WATCHMAN FLX, Zypitamag | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error